1183 related articles for article (PubMed ID: 27435367)
1. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
3. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
4. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
[TBL] [Abstract][Full Text] [Related]
5. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
6. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
8. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
9. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
10. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
11. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
12. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
Hatashita S; Yamasaki H
PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
[TBL] [Abstract][Full Text] [Related]
13. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
14. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054
[TBL] [Abstract][Full Text] [Related]
15. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
17. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
20. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.
Parbo P; Ismail R; Sommerauer M; Stokholm MG; Hansen AK; Hansen KV; Amidi A; Schaldemose JL; Gottrup H; Brændgaard H; Eskildsen SF; Borghammer P; Hinz R; Aanerud J; Brooks DJ
Neurobiol Dis; 2018 Sep; 117():211-216. PubMed ID: 29902557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
